Page 1794 - Williams Hematology ( PDFDrive )

1768 Part XI: Malignant Lymphoid Diseases Chapter 107: Myeloma 1769

451. Richardson PG, Barlogie B, Berenson J, et al: Extended follow-up of a phase II trial in 479. Orlowski RZ, Nagler A, Sonneveld P, et al: Randomized phase III study of pegylated
relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed
trial. Cancer 106:1316–1319, 2006. or refractory multiple myeloma: Combination therapy improves time to progression. J
452. Jagannath S, Barlogie B, Berenson JR, et al: Updated survival analyses after prolonged Clin Oncol 25:3892–3901, 2007.
follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refrac- 480. Pineda-Roman M, Zangari M, van Rhee F, et al: VTD combination therapy with borte-
tory multiple myeloma. Br J Haematol 143:537–540, 2008. zomib-thalidomide-dexamethasone is highly effective in advanced and refractory mul-
453. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexametha- tiple myeloma. Leukemia 22:1419–1427, 2008.
sone for relapsed multiple myeloma. N Engl J Med 352:2487–2498, 2005. 481. Ponisch W, Rozanski M, Goldschmidt H, et al: Combined bendamustine, prednisolone
454. Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell
in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood transplantation or conventional chemotherapy: Results of a phase I clinical trial. Br J
110:3557–3560, 2007. Haematol 143:191–200, 2008.
455. Mikhael JR, Belch AR, Prince HM, et al: High response rate to bortezomib with or with- 482. Palumbo A, Dimopoulos M, San Miguel J, et al: Lenalidomide in combination with
out dexamethasone in patients with relapsed or refractory multiple myeloma: Results of dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood
a global phase 3b expanded access program. Br J Haematol 144:169–175, 2009. Rev 23:87–93, 2009.
456. Kumar SK, Bensinger WI , Zimmerman TM, et al: Weekly MLN9708, an investigational 483. Lonial SS, Shah J, Zonder JA, et al: Prolonged survival and improved response rates with
oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results ARRY-520 (Filanesib) in relapsed/refractory multiple myeloma (RRMM) patients with
from a phase I study after full enrollment. J Clin Oncol 31, 2013. low α-1 acid glycoprotein (AAG) levels: Results from a phase 2 study. Blood Abstract 653,
457. Richardson PG, Hofmeister CC, Rosenbaum CA, et al: Twice-weekly oral MLN9708 2013.
(Ixazomib Citrate), an investigational proteasome inhibitor, in combination with 484. Chari AH, Htut M, Zonder JA, et al: A phase 1 study of ARRY-520 (Filanesib) with
lenalidomide (len) and dexamethasone (Dex) in patients (Pts) with newly diagnosed bortezomib (BTZ) and dexamethasone (DEX) in relapsed or refractory multiple mye-
multiple myeloma (MM): Final phase 1 results and phase 2 data. Blood Abstract 535, loma (RRMM). Blood 2013.
2013. 485. Santo L, Vallet S, Hideshima T, et al: AT7519, a novel small molecule multi-cyclin-de-
458. van Rhee F, Dhodapkar M, Shaughnessy JD Jr, et al: First thalidomide clinical trial in pendent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activa-
multiple myeloma: A decade. Blood 112:1035–1038, 2008. tion and RNA polymerase II inhibition. Oncogene 29:2325–2336, 2010.
459. Palumbo A, Giaccone L, Bertola A, et al: Low-dose thalidomide plus dexamethasone is 486. Chaidos A, Caputo V, Gouvedenou K, et al: Potent antimyeloma activity of the novel
an effective salvage therapy for advanced myeloma. Haematologica 86:399–403, 2001. bromodomain inhibitors I-BET151 and I-BET762. Blood 123:697–705, 2014.
460. Dimopoulos MA, Zervas K, Kouvatseas G, et al: Thalidomide and dexamethasone com- 487. Chauhan D, Tian Z, Nicholson B, et al: A small molecule inhibitor of ubiquitin-specific
bination for refractory multiple myeloma. Ann Oncol 12:991–995, 2001. protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib
461. Anagnostopoulos A, Weber D, Rankin K, et al: Thalidomide and dexamethasone for resistance. Cancer Cell 22:345–358, 2012.
resistant multiple myeloma. Br J Haematol 121:768–771, 2003. 488. Rosenblatt JA, Avivi I, Vasir D, et al: Blockade of PD-1 in combination with dendritic
462. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed cell/myeloma fusion cell vaccination following autologous stem cell transplantation.
multiple myeloma in North America. N Engl J Med 357:2133–2142, 2007. Blood 2012.
463. Chen C, Reece DE, Siegel D, et al: Expanded safety experience with lenalidomide 489. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al: Donor leukocyte infusions are
plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 146: effective in relapsed multiple myeloma after allogeneic bone marrow transplant. Blood
164–170, 2009. 90:4206–4211, 1997.
464. Richardson PG, Siegel DS, Vij R, et al: Pomalidomide alone or in combination with 490. Tricot G, Vesole DH, Jagannath S, et al: Graft-versus-myeloma effect: Proof of principle.
low-dose dexamethasone in relapsed and refractory multiple myeloma; a randomized Blood 87:1196–1198, 1996.
phase 2 study. Blood 123:1826–1832, 2014. 491. Bird JM, Russell NH, Samson D: Minimal residual disease after bone marrow trans-
465. Dimopoulos ML, Moreau M, P et al: Pomalidomide in combination with low-dose plant for multiple myeloma: Evidence for cure in long-term survivors. Bone Marrow
dexamethasone; demonstrates significant progression free survival and overall survival Transplant 12:651–654, 1993.
advantage, in relapsed/refractory MM: A phase 3, multicenter, randomized, open-label 492. Corradini P, Voena C, Tarella C, et al: Molecular and clinical remissions in multiple
study. Blood 120, 2012. myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J
466. Dimopoulos M, Siegel DS, Lonial S, et al: Vorinostat or placebo in combination with Clin Oncol 17:208–215, 1999.
bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, ran- 493. Alyea E, Weller E, Schlossman R, et al: Outcome after autologous and allogeneic stem
domised, double-blind study. Lancet Oncol 14:1129–1140, 2013. cell transplantation for patients with multiple myeloma: Impact of graft-versus-mye-
467. Richardson PG, Yoon V, S et al: Panorama 1: A randomized double-blind, phase 3 study loma effect. Bone Marrow Transplant 32:1145–1151, 2003.
of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or refrac- 494. Bensinger WI, Buckner CD, Anasetti C, et al: Allogeneic marrow transplantation for
tory multiple myeloma. J Clin Oncol 32:suppl: Abstract 8510, 2014. multiple myeloma: An analysis of risk factors on outcome. Blood 88:2787–2793, 1996.
468. Yee AV, P, Bensinger, W et al: ACY-1215, a selective histone deacetylase (HDAC) 6 495. Bjorkstrand BB, Ljungman P, Svensson H, et al: Allogeneic bone marrow transplant
inhibitor, in combination with lenalidomide and dexamethasone, is well tolerated with versus autologous stem cell transplantation in multiple myeloma: A retrospective case-
dose-limiting toxicity in patients with multiple myeloma (MM) at doses demonstrating matched study from the European Group for Blood and Marrow Transplantation. Blood
biologic activity: Interim results of a phase Ib trial. Blood 2013. 88:4711–4718, 1996.
469. Raje NV, Hari D, p et al: ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: 496. Gahrton G, Tura S, Ljungman P, et al: Allogeneic bone marrow transplant in multiple
Interim results of combination therapy with multiple myeloma. Blood 2013. myeloma. European Group for Bone Marrow Transplant. N Engl J Med 325:1267–1273,
470. Lokhorst HP, Gimsing T, P et al: Phase I/II dose-escalation study of daratumumab in 1991.
patients with relapsed or refractory multiple myeloma. J Clin Oncol 31:suppl: Abstract 497. Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow
8512, 2013. transplant for multiple myeloma. J Clin Oncol 13:1312–1322, 1995.
471. Martin TG, Strickland SA, Glenn M, et al: SAR650984, a CD38 monoclonal antibody 498. Hunter HM, Peggs K, Powles R, et al: Analysis of outcome following allogeneic haemo-
in patients with selected CD38+ hematological malignancies—Data from a dose-esca- poietic stem cell transplantation for myeloma using myeloablative conditioning—evi-
lation phase I study. Blood 2013. dence for a superior outcome using melphalan combined with total body irradiation.
472. Zonder JA, Mohrbacher AF, Singhal S, et al: A phase 1, multicenter, open-label, dose Br J Haematol 128:496–502, 2005.
escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 499. Reece DE, Shepherd JD, Klingemann HG, et al: Treatment of myeloma using intensive ther-
120:552–559, 2012. apy and allogeneic bone marrow transplant. Bone Marrow Transplant 15:117–123, 1995.
473. Lonial S, Vij R, Harousseau JL, et al: Elotuzumab in combination with lenalidomide 500. Varterasian M, Janakiraman N, Karanes C, et al: Transplantation in patients with mul-
and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol tiple myeloma: A multicenter comparative analysis of peripheral blood stem cell and
30:1953–1959, 2012. allogeneic transplant. Am J Clin Oncol 20:462–466, 1997.
474. Jakubowiak AJ, Benson DM, Bensinger W, et al: Phase I trial of anti-CS1 monoclonal 501. Bensinger WI, Demirer T, Buckner CD, et al: Syngeneic marrow transplantation in
antibody elotuzumab in combination with bortezomib in the treatment of relapsed/ patients with multiple myeloma. Bone Marrow Transplant 18:527–531, 1996.
refractory multiple myeloma. J Clin Oncol 30:1960–1965, 2012. 502. Gahrton G, Svensson H, Bjorkstrand B, et al: Syngeneic transplantation in multiple
475. Raje NF, Faber E, Richardson P, et al: Phase 1 study of tabalumab, a human anti-BAFF myeloma-a case-matched comparison with autologous and allogeneic transplantation.
antibody and bortezomib in patients with previously-treated multiple myeloma. Blood European Group for Blood and Marrow Transplantation. Bone Marrow Transplant
2012. 24:741–745, 1999.
476. Lentzsch S, O’Sullivan A, Kennedy RC, et al: Combination of bendamustine, lenalido- 503. Gahrton G, Svensson H, Cavo M, et al: Progress in allogenic bone marrow and periph-
mide, and dexamethasone (BLD) in patients with relapsed or refractory multiple mye- eral blood stem cell transplantation for multiple myeloma: A comparison between
loma is feasible and highly effective: Results of phase 1/2 open-label, dose escalation transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow
study. Blood 119:4608–4613, 2012. Transplantation centres. Br J Haematol 113:209–216, 2001.
477. Knop S, Straka C, Haen M, et al: The efficacy and toxicity of bendamustine in recurrent 504. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor
multiple myeloma after high-dose chemotherapy. Haematologica 90:1287–1288, 2005. cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia
478. Chanan-Khan AA, Niesvizky R, Hohl RJ, et al: Phase III randomised study of dex- without myeloablative therapy. Blood 89:4531–4536, 1997.
amethasone with or without oblimersen sodium for patients with advanced multiple 505. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation
myeloma. Leuk Lymphoma 50:559–565, 2009. and cell therapy as an alternative to conventional bone marrow transplant with lethal

Kaushansky_chapter 107_p1733-1772.indd 1769 9/21/15 12:36 PM